Abeona therapeutics announces aav204, a novel aav capsid, demonstrated robust macular transduction following para-retinal administration in non-human primates

New york and cleveland, ohio, may 04, 2022 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo), a fully-integrated leader in cell and gene therapy, today announced the presentation of new preclinical data on aav204 at the association for research and vision in ophthalmology (arvo) annual meeting, taking place on may 1-4, 2022 in denver, co and virtually on may 11-12, 2022. the data was featured in a poster presentation entitled “aav204, a novel aav capsid, demonstrates superior macular transduction following para-retinal administration in non-human primates.”
ABEO Ratings Summary
ABEO Quant Ranking